{"editorial":{"content_id":"88611b26-3418-4b0a-850b-fae44c307c27","slug":"apsen-luratt-20261112-1ac095","content_type":"news","title":"巴西Apsen推出首款抗精神病药Luratt，拓展中枢神经系统产品线","summary":"巴西制药公司Apsen宣布推出其首个抗精神病药物Luratt（盐酸鲁拉西酮），用于治疗精神分裂症及双相情感障碍相关抑郁发作。","body":"巴西制药公司Apsen宣布推出Luratt（盐酸鲁拉西酮），这是该公司首个抗精神病药物，也是治疗精神分裂症及双相情感障碍相关抑郁发作的新治疗选择。产品提供20毫克、40毫克和80毫克三种规格的包衣片剂。\n\n据Apsen介绍，该药物分子在代谢方面具有特点，与其他同类药物相比，出现显著体重增加以及胆固醇和血糖水平变化的风险较低。鲁拉西酮作为多巴胺D2受体和5-羟色胺5-HT2A受体的拮抗剂，这两种受体参与调节精神病性症状和情绪。\n\nLuratt适用于15岁及以上青少年和成人的精神分裂症治疗；对于双相情感障碍相关抑郁发作，适用患者为13岁及以上。该药可单独使用，也可与锂盐或丙戊酸盐等心境稳定剂联用。\n\n用药方式为每日一次，需随至少350卡路里的餐食服用，这是药物充分吸收的必要条件。鲁拉西酮还可能有助于改善认知和行为方面的表现。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["企业动态","行业趋势","br-health"],"content_level":"编辑整理","event_type":"公司动态","audience_tags":[],"event_location":null,"verification_status":"unverified","published_at":"2026-11-12T17:04:43.106Z","display_date":"2026-11-12","source_published_at":null,"source_url":"https://panoramafarmaceutico.com.br/apsen-amplia-portfolio-de-snc/","source_name":"Panorama Farmacêutico","source_language":"pt","author_name":"编辑部","risk_level":"medium","risk_flags":[],"opportunity_flags":["market_entry_opportunity"],"trend_signals":[]},"intelligence":{"intel_id":"c7367f27-163d-4495-8d1d-9689de54e114","version":1,"event_type":"产品上线","event_date":null,"main_entities":[{"name":"Apsen","role":"巴西制药公司，Luratt的推出方，借此拓展中枢神经系统产品线","type":"company","country":"巴西","normalized_name":null},{"name":"Luratt","role":"Apsen推出的首款抗精神病药物，商品名","type":"product","country":"巴西","normalized_name":null},{"name":"盐酸鲁拉西酮","role":"Luratt的活性成分，多巴胺D2受体和5-羟色胺5-HT2A受体拮抗剂","type":"product","country":"其他","normalized_name":null}],"main_action":"Apsen在巴西推出首款抗精神病药Luratt，拓展中枢神经系统产品线","key_numbers":[{"unit":"毫克","label":"Luratt规格","value":"20/40/80"},{"unit":"岁及以上","label":"精神分裂症适用年龄","value":"15"},{"unit":"岁及以上","label":"双相情感障碍相关抑郁发作适用年龄","value":"13"},{"unit":"次/日","label":"给药频率","value":"1"},{"unit":"卡路里","label":"随餐最低热量","value":"350"}],"facts":[{"verified":false,"statement":"巴西制药公司Apsen宣布推出Luratt（盐酸鲁拉西酮）。","source_excerpt":null},{"verified":false,"statement":"Luratt提供20毫克、40毫克和80毫克三种规格的包衣片剂。","source_excerpt":null},{"verified":false,"statement":"Luratt适用于15岁及以上青少年和成人的精神分裂症治疗。","source_excerpt":null},{"verified":false,"statement":"Luratt适用于13岁及以上患者的双相情感障碍相关抑郁发作。","source_excerpt":null},{"verified":false,"statement":"Luratt每日一次，需随至少350卡路里的餐食服用。","source_excerpt":null},{"verified":false,"statement":"鲁拉西酮是多巴胺D2受体和5-羟色胺5-HT2A受体的拮抗剂。","source_excerpt":null}],"assessments":[{"statement":"Apsen通过推出Luratt进入抗精神病药物市场，并扩展其中枢神经系统产品组合。","confidence":"high","basis_fact_index":null},{"statement":"相较部分同类药物，Luratt在体重增加及胆固醇、血糖变化风险方面的代谢特点可能形成差异化卖点。","confidence":"medium","basis_fact_index":null},{"statement":"每日一次但需随至少350卡路里餐食服用的要求，可能对部分患者用药依从性构成挑战。","confidence":"medium","basis_fact_index":null}],"actions":[{"target":"system","priority":"high","description":"跟踪Apsen在巴西的ANVISA注册/审批状态、上市日期及产品定价信息。"},{"target":"user","priority":"normal","description":"关注Apsen中枢神经系统产品线后续扩展及与现有抗精神病药物的竞争格局。"},{"target":"both","priority":"normal","description":"监测Luratt上市后的处方覆盖、医保报销及安全性信息。"}],"affected_audience":["精神分裂症患者","双相情感障碍相关抑郁发作患者","15岁及以上青少年和成人精神分裂症患者","13岁及以上双相情感障碍相关抑郁发作患者","处方医生","巴西中枢神经系统药物市场参与者"],"risk_flags":[],"opportunity_flags":["market_entry_opportunity"],"trend_signals":[],"follow_up_needed":true,"follow_up_questions":["Luratt在巴西是否已获得ANVISA批准，具体上市日期和注册状态如何？","Luratt在巴西的定价、医保报销和商业可及性安排是什么？","Apsen是否计划进一步扩充中枢神经系统产品线或开展本地生产？","Luratt与巴西市场现有抗精神病药物相比的实际处方和竞争表现如何？"],"related_topics":["巴西制药行业","Apsen","Luratt","盐酸鲁拉西酮","抗精神病药","精神分裂症","双相情感障碍","中枢神经系统"],"verification_status":"unverified","confidence_score":0.7,"generated_at":"2026-11-12T17:05:01.247Z"},"meta":{"canonical_url":"https://chinabrazilinsight.com/news/apsen-luratt-20261112-1ac095","api_url":"https://chinabrazilinsight.com/api/public/content/apsen-luratt-20261112-1ac095","markdown_url":"https://chinabrazilinsight.com/api/public/content/apsen-luratt-20261112-1ac095?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/apsen-luratt-20261112-1ac095?view=json","last_updated":"2026-11-12T17:05:01.349Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}